SymbioCellTech

Symbio Cell Tech

Biotechnology, 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States, 1-10 Employees

symbiocelltech.com

  • LinkedIn

phone no Phone Number: +18*********

Who is SYMBIOCELLTECH

SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be ...

Read More

map
  • 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States Headquarters: 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States
  • 2014 Date Founded: 2014
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from SYMBIOCELLTECH

SymbioCellTech Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SymbioCellTech

Answer: SymbioCellTech's headquarters are located at 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States

Answer: SymbioCellTech's phone number is +18*********

Answer: SymbioCellTech's official website is https://symbiocelltech.com

Answer: SymbioCellTech's revenue is Under $1 Million

Answer: SymbioCellTech's SIC: 8731

Answer: SymbioCellTech has 1-10 employees

Answer: SymbioCellTech is in Biotechnology

Answer: SymbioCellTech contact info: Phone number: +18********* Website: https://symbiocelltech.com

Answer: SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access